The overarching purpose of this opportunity is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this scheme is on the identification and initial biological, analytical, and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints.
Although research supported by this award can include animal studies, it must also include preliminary human validation using carefully standardised human samples, or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.
Funding & Duration
Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period of the combined R61 and R33 phases is five years, with up to three years for the R61 phase and up to two years for the R33 phase.
Any for-profit recipients of funds shall be subject to a matching requirement of funds or documented in-kind contributions of not less than 50 per cent of the total funds awarded to such entities.
US and foreign for-profit and non-profit organisations and public and private organisations may apply.
Submission Requirements & Due Date
- 28 October 2018 – Letter of Intent submitted to Sponsor
- 13 November 2018 – applications submitted to Research Services for internal review.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review